Doximity and OpenEvidence Settle AI Lawsuits

The two companies have reached an agreement ending legal battles over accusations of trade secret theft and misinformation.

Updated on Oct. 20, 2026 in Healthcare

Doximity and OpenEvidence Settle AI Lawsuits

Live Poll

Should tech companies face stricter legal consequences for using potentially stolen code to train AI?

Doximity and OpenEvidence have settled their legal disputes, which centered on allegations of intellectual property theft and malicious misinformation. The conflict arose following Doximity's acquisition of a firm accused of misappropriating proprietary code.

Why it matters

The settlement resolves a high-profile dispute involving the development of clinical AI models. It addresses serious accusations regarding the use of prompt injection attacks and the integrity of trade secrets in the competitive healthcare technology sector.

Doximity acquired Pathway Medical for $63 million in August 2025. This acquisition served as the focal point for the trade secret theft allegations brought by OpenEvidence.

The players

Doximity

Doximity is a digital platform for medical professionals that provides networking, career management, and clinical information tools.

OpenEvidence

OpenEvidence is a technology company focused on developing AI models for clinical and medical applications.

Pathway Medical

Pathway Medical was a health technology company acquired by Doximity in 2025.

Business Insider

Business Insider is a global news publication covering business, technology, and financial industries.

The details

OpenEvidence alleged that Doximity and the acquired firm, Pathway Medical, utilized stolen proprietary code and prompt injection attacks against its chatbot to build competing clinical AI models. Doximity countered by accusing OpenEvidence of spreading misinformation to damage its reputation and recruit employees.

February 2025: OpenEvidence sued Pathway Medical for the theft of trade secrets.
Summer 2025: OpenEvidence initiated a lawsuit against Doximity.
August 2025: Doximity completed the acquisition of Pathway Medical for $63 million.
September 2025: Business Insider reported on the conflict.
October 2026: The companies announced a settlement of the lawsuits.

Market Landscape

The settlement of the 2025 trade secret litigation between OpenEvidence and Doximity reflects the high stakes of intellectual property protection in the rapid evolution of clinical AI. This agreement concludes a contentious chapter that highlighted the competitive intensity and risks surrounding data security in the healthcare tech sector.

Users of clinical AI tools and healthcare software should monitor for any changes in service availability or features as Doximity integrates its acquired technologies. The settlement reduces the risk of sudden disruptions to platforms that rely on the clinical models developed by these companies.

The takeaway

Legal disputes over proprietary data highlight the importance of intellectual property due diligence during corporate acquisitions. Organizations should prioritize secure data handling to avoid costly litigation that can divert resources from product development.